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Insulin-like growth factor (IGF)-I has cancer promoting activities. However, the hypothesis that circulating IGF-I concentration
is related to risk of lymphoma overall or its subtypes has not been examined prospectively. IGF-I concentration was measured
in pre-diagnostic plasma samples from a nested case–control study of 1,072 cases of lymphoid malignancies and 1,072 indi-
vidually matched controls from the European Prospective Investigation into Cancer and Nutrition. Odds ratios (ORs) and confi-
dence intervals (CIs) for lymphoma were calculated using conditional logistic regression. IGF-I concentration was not
associated with overall lymphoma risk (multivariable-adjusted OR for highest versus lowest third50.77 [95% CI50.57–
1.03], ptrend50.06). There was no statistical evidence of heterogeneity in this association with IGF-I by sex, age at blood col-
lection, time between blood collection and diagnosis, age at diagnosis, or body mass index (pheterogeneity for all0.05). There
were no associations between IGF-I concentration and risk for specific BCL subtypes, T-cell lymphoma or Hodgkin lymphoma,
although number of cases were small. In this European population, IGF-I concentration was not associated with risk of overall
lymphoma. This study provides the first prospective evidence on circulating IGF-I concentrations and risk of lymphoma. Further
prospective data are required to examine associations of IGF-I concentrations with lymphoma subtypes.
Despite the major impact of lymphoma on public health, rel-
atively little is known about the aetiology of this group of
malignancies, and the few established risk factors include age,
family history, genetic factors, immunosuppression and viral
infections.1 Insulin-like growth factors (IGFs) have potential
cancer promoting activities and circulating concentrations of
IGF-I have been shown to be associated with risk for devel-
oping several types of cancer.2,3 However, the hypothesis that
IGF-I is related to overall lymphoma risk has not yet been
examined prospectively.
What’s new?
Insulin-like growth factor I does not appear to influence lymphoma risk, according to new results. IGF-I can promote some can-
cers, but there hasn’t been a prospective epidemiological study examining the link between IGF-I concentration and lymphoma
risk. To uncover a link, these authors arranged a NESTED case–control study with participants from the European Prospective
Investigation into Cancer and Nutrition (EPIC). They tested for IGF-I in pre-diagnosis samples and found no association
between the factor and overall lymphoma risk, nor with any subtype, although the number of cases was small for each sub-
type, and further studies are nec ssary.
C
an
ce
r
E
pi
de
m
io
lo
gy
1112 Plasma IGF-I and lymphoma risk in EPIC
Int. J. Cancer: 140, 1111–1118 (2017) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
IGF-I is a polypeptide growth factor that is primarily pro-
duced in the liver under the stimulus of growth hormone.4 It
is involved in the promotion of cell growth and prevention
of apoptosis in many tissue types, including cancer cells in
several malignancies, and can act in an endocrine, paracrine or
autocrine manner.4 Evidence from in vitro studies and clinical
reports supports a potential role of IGFs in the aetiology of
hematological tumours, including lymphoma.5 Elevated IGF-I
concentrations may activate the PI3-K/AKT and b1-integrin
signalling pathways in lymphoma cells, contributing to carci-
nogenesis,6 and there is some experimental evidence that IGF-
I may induce growth and survival of lymphoma cells.7
Lymphomas include a range of heterogeneous malignancies
that originate from lymphocytes and recent evidence suggests
aetiological heterogeneity of different lymphoma subtypes. IGF-I
has been found to be mitogenic for multiple myeloma (MM) cells
both in vitro and in vivo.7,8 However, there are few published data
on circulating concentrations of IGFs in patients with haematolog-
ical malignancies 9–11 and there have been no prospective investi-
gations of IGF-I and overall lymphoma incidence.
In this study, we will examine the relationship between pre-
diagnostic circulating concentration of IGF-I and subsequent risk
of overall lymphoma and lymphoma subtypes in the European
Prospective Investigation into Cancer and Nutrition (EPIC).
Material and Methods
Study cohort
The EPIC cohort consists of approximately 500,000 individuals
recruited between 1992 and 2000 from 23 centres in 10 Europe-
an countries (Denmark, France, Germany, Greece, Italy, The
Netherlands, Norway, Spain, Sweden, and the United King-
dom). The main aim of this cohort was to investigate the rela-
tionship between nutrition and cancer. Participant eligibility
within each cohort was based essentially on geographic or
administrative boundaries, mostly aged 35 to 70 years.12 Partici-
pants were mostly recruited from the general population, but
there were some exceptions. Participants residing in Spain and
Italy (Ragusa and Turin) comprise blood donors and their
spouses, members of several health insurance schemes, employ-
ees of several enterprises, civil servants and the general popula-
tion. Also, the Oxford cohort (UK) included a large number of
vegetarians and health-conscious participants. Participants pro-
vided detailed information on dietary and non-dietary factors at
recruitment, which took place between 1992 and 2000, and
about 400,000 individuals also provided a blood sample.
Follow-up aimed at identifying cancer cases was mainly by
population-based cancer registries. In France, Germany and
Greece, follow-up was based on a combination of methods,
including health insurance records, cancer and pathology regis-
tries, as well as active follow-up through participants or rela-
tives; self-reported incident cancers were veriﬁed through
medical records. All participants gave informed consent, and
approval of the study was obtained from the Internal Review
Board of the International Agency for Research on Cancer
(IARC) (Lyon, France) and from ethics committees at the
participating institutions. Further details of the methods of
recruitment and study design have been described in detail
elsewhere.12
Whole blood was aliquoted generally within 24 hr into
separate plasma, serum, buffy coat and erythrocyte fractions
and stored in liquid nitrogen (21968C) at IARC (except for
Denmark and Sweden where all samples were stored locally).
Selection of cases and controls
The present nested case–control study includes lymphoma
cases diagnosed after blood collection and individually
matched control participants from nine participating countries:
Denmark, Germany, Greece, Italy, The Netherlands, Norway,
Spain, Sweden and the UK. Due to incomplete coding for lym-
phoid neoplasms, participants from France were not included
in the current analysis (n5 68,050). In Germany and Greece,
follow-up is active and is achieved through checks of health
insurance records, cancer and pathology registries or via self-
reported questionnaires, while in the remaining countries it is
achieved through linkage to national cancer registries.
Participants were eligible for this analysis if they had infor-
mation available on the date of blood collection and did not
have a history of cancer (except non-melanoma skin cancer)
at the time of the blood collection (n5 27,089 were excluded).
Cases were eligible for inclusion if they were diagnosed with
lymphoma after the date of blood collection until the end of
the follow-up period. Each case patient was matched to one
control participant, selected at random among appropriate risk
sets consisting of all cohort members alive and free of cancer
(except non-melanoma skin cancer) after the same amount of
follow-up time as the index case. An incidence density sam-
pling protocol for control selection was used, such that con-
trols could include participants who became a case later in
time, while each control participant could also be sampled
more than once. Matching criteria were: recruitment centre,
sex, age at recruitment (612 months), date at recruitment
(63 months), duration of follow-up, and time of day (61 hr)
and fasting status at blood collection (Supporting Information
Figure 1). The ﬁnal sample comprised 1,072 cases and 1,072
controls with a mean follow-up time of 9 years (SD: 2 years).
While lymphomas have traditionally been classiﬁed as
either Hodgkin lymphoma (HL) or non-Hodgkin lymphoma
(NHL), in this analysis lymphomas were categorised, as in
previous EPIC lymphoma papers,13 according to the current
World Health Organization (WHO) classiﬁcation of haema-
topoietic and lymphoid tumours,14 which differentiates
between B-cell neoplasms, T-cell tumours, HL, and based on
distinct morphologic, immunophenotypic, and genetic fea-
tures. Cases comprised 897 B-cell lymphoma (BCL), 34 T-
cell, 51 HL, and 90 other subtypes of lymphoma. The 897
BCL cases were further categorised into 124 diffuse large B-
cell lymphoma (DLBCL), 115 follicular lymphoma (FL), 184
B-cell chronic lymphocytic leukemia (B-CLL), 237 MM 237
other subtypes of BCL [i.e. those cases for which the BCL
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subtype is unknown or does not fall within the more com-
mon BCL subtypes (i.e. DBCL, FL, B-CLL or MM)].
Laboratory assays
Plasma IGF-I concentrations were measured using the auto-
mated IDS-iSYS immunoassay system from Immunodiagnostic
Systems (IDS) Ltd. at the Cancer Epidemiology Unit laborato-
ry (University of Oxford, UK). Two quality control samples
prepared from commercially available pooled plasma (from
Seralabs) were assayed with every 20 study participant sam-
ples. The overall coefﬁcient of variation was 4.3% at a mean
concentration of 10.8 nmol/L. The lower limit of detection was
1.3 nmol/L for the IDS-iSYS immunoassay, adequate to detect
the lowest concentration in all study samples.
Statistical analysis
Differences in baseline characteristics of cases and controls
were compared using paired t-tests for continuous variables
and v2 tests or conditional logistic regression models for cate-
gorical variables, comparing the value for the case with the
value in the matched control participant. For cases only,
years between blood collection and diagnosis, age at diagnosis
and type of lymphoid malignancy were additionally reported.
For all analyses, concentrations of IGF-I were transformed
logarithmically to approximate a normal distribution. Condition-
al logistic regression models were applied to calculate the relative
risks (odds ratios [ORs]) for total lymphoma, BCL subtypes, T-
cell lymphoma, and HL in relation to thirds of IGF-I concentra-
tion using cut points deﬁned by the sex-speciﬁc tertiles among
control participants for all centres combined and using the low-
est category as reference. Analyses of risk of overall lymphoma
were conditioned on the matching variables, and were also con-
ducted with additional adjustment for smoking (never, past, cur-
rent), body mass index (BMI, kg/m2; in fourths), physical
activity (inactive, moderately inactive, moderately active/active),15
alcohol intake (<8, 8–15, 16–39, 40 g/day), marital status
(married/cohabiting or not married/cohabiting) and education
level (primary or equivalent, secondary, degree level). For each
of these variables a small proportion of values were unknown
(participants with missing data on the covariates were assigned
to an “unknown” category; <11% of values missing for each,
with the exception of marital status, for which 32% of values
were missing); these observations were included in the analyses
as a separate “unknown” category. For subtypes of BCL, and for
T-cell and HL, analyses were conditioned on the matching varia-
bles but were not conducted with additional adjustments because
of the small number of cases for these less common lymphoma
subtypes. Tests for linear trend were obtained using a continuous
variable with values equal to the median concentration within
each tertile of plasma IGF-I concentration.
The heterogeneity of the ORs by sex, age at blood collec-
tion (<60 or 60 years), time between blood collection and
diagnosis (<48 or 48 months), age at diagnosis (<60 or
60 years) and BMI (<25 or 25 kg/m2), was examined
using likelihood ratio v2 tests, based on models with and
without an interaction term between IGF-I concentration and
the variable of interest.
Statistical analyses were performed with the Stata 14.0 statis-
tical software package.16 All tests of statistical signiﬁcance were
two-sided and p values below 0.05 were considered signiﬁcant.
Results
The baseline characteristics of the 1,072 lymphoma cases and
1,072 participants without lymphoma (controls) are provided
in Table 1. Case and control subjects were similar with
respect to age, BMI, smoking status, physical activity, marital
status, and educational level. The overall median age at blood
collection was 57.5 years (range: 29.6–79.2 years). Partici-
pants with lymphoma were diagnosed an average 4.9 years
after blood collection (range: <1–13 years) and the median
age at diagnosis was 61.9 years (range: 33–83 years).
Age at blood collection, BMI, and geometric mean circu-
lating concentrations of plasma IGF-I of case patients and
control participants are shown in Supporting Information
Table 1. Mean IGF-I concentration was slightly lower in
cases than controls (15.5 vs. 15.9 nmol/L, respectively; p 5
0.05), and this difference was particularly evident for those
diagnosed with “other subtypes of BCL” (unknown BCL sub-
type or does not fall within the more common BCL subtypes)
(15.2 vs. 15.9 nmol/L in cases vs. controls, p 5 0.004).
The association between circulating IGF-I concentration
and lymphoma risk is shown in Table 2. After adjustment
for smoking, physical activity, alcohol intake, marital status,
education and BMI, the OR for the highest versus the lowest
third of IGF-I concentration was 0.82, 95% CI: 0.65–1.02;
ptrend5 0.06 for overall lymphoma. Analyses of the associa-
tion of IGF-I concentration with rarer subtypes of lymphoma
showed no signiﬁcant association with DLBCL, FL, B-CLL,
MM, T-NHL or HL, although numbers of cases were small.
Finally, there was no evidence of heterogeneity in the associa-
tion of IGF-I and risk of overall lymphoma (Table 3) by sex
(pheterogeneity5 0.08), age at blood collection (pheterogeneity5 0.3),
time between blood collection and diagnosis (pheterogeneity5 0.9),
age at diagnosis (pheterogeneity 5 0.2), or BMI (pheterogeneity5 0.09).
Discussion
In this large European prospective study, plasma concentra-
tion of IGF-I was not associated with overall risk for
lymphoma.
To date, most of the data on the relationship between
IGF-I with risk of overall lymphoma come from in vitro or
in vivo studies, and to our knowledge, this is the ﬁrst large-
scale prospective epidemiological study to examine this asso-
ciation. One previous prospective study assessed the associa-
tion between pre-diagnosis IGF-I and risk of MM and found
no signiﬁcant association.11 In the few clinical and retrospec-
tive studies of the IGF axis in relation to lymphoma, circulat-
ing IGF-I concentrations have been found variously to be
low in 84 survivors of childhood NHL,17 to not differ at diag-
nosis between 57 MM patients and 20 controls,9 and to be
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related to prognosis for MM patients (with low serum IGF-I
at diagnosis being associated with favourable prognosis).18 A
recent study in classical HL patients has shown that despite
the oncogenic effect of IGF-IR, a higher expression at diagno-
sis predicted a favourable outcome both for overall survival
and 5-year progression-free survival.19 In the current
Table 1. Characteristics of lymphoma cases and matched controls participants in EPIC
Cases (n51072) Controls (n51072) p1
Male, n (%) 559 (52.1) 559 (52.1)
Age at blood collection, yr2 57.5 (8.0) 57.5 (8.0)
Age at diagnosis, yr2 61.9 (8.1)
Years between blood collection and diagnosis b 4.9 (2.8)
BMI (kg/m2)2 26.4 (4.2) 26.3 (3.9) 0.5
Alcohol at recruitment (g/d)2 1.94 (1.16) 1.92 (1.17) 0.7
Smoking status, n (%) 0.4
Never 428 (39.9) 456 (42.5)
Former 382 (35.6) 347 (32.4)
Current smoker 247 (23.0) 257 (24.0)
Unknown 15 (1.4) 12 (1.1)
Physical activity, n (%) 0.9
Inactive 237 (22.1) 237 (22.1)
Moderately inactive 307 (28.6) 306 (28.5)
Moderately active 201 (18.8) 206 (19.2)
Active 209 (19.5) 212 (19.8)
Unknown 118 (11.0) 111 (10.4)
Marital status, n (%) 0.7
Married 580 (54.1) 577 (53.8)
Single 136 (12.7) 148 (13.8)
Unknown 356 (33.2) 347 (32.4)
Education, n (%) 0.3
Primary school/none 396 (36.9) 436 (40.7)
Secondary 439 (41.0) 411 (38.3)
Degree 193 (18.0) 187 (17.4)
Unknown 44 (4.1) 38 (3.5)
Lymphoma type, n (%)
BCL 897 (83.7)
DLBCL 124 (11.6)
FL 115 (10.7)
B-CLL 184 (17.2)
MM 237 (22.1)
Other subtypes of BCL3 237 (22.1)
T-NHL 34 (3.2)
HL 51 (4.8)
Other subtypes of lymphoma 90 (8.4)
IGF-I (nmol/L)4 15.5 (15.3–15.8) 15.9 (15.6–16.2) 0.05
1Two-sided p values for difference from paired t-test, comparing concentrations within matched case control pair and v2 test for categorical variables.
2Mean (SD).
3Those cases for which the BCL subtype is unknown or does not fall within the more common BCL subtypes (i.e. DBCL, FL, B-CLL or MM).
4Geometric mean (95% CI).
Abbreviations: N, number; BCL, B-cell lymphoma; B-CLL, B-cell chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular
lymphoma; HL, Hodgkin lymphoma; IGF-I, insulin-like growth factor I; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.
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prospective study, the association between IGF-I and overall
lymphoma risk was close to signiﬁcant; however, we had rel-
atively limited sample size and lymphoma is a heterogeneous
disease.20 Therefore, further prospective analyses of the asso-
ciation in studies with information on lymphoma subtype are
warranted.
We observed that IGF-I concentrations were not associat-
ed with the incidence of the common BCL subtypes (DLBCL,
FL, MM, B-CLL and MM), although the number of cases for
most subtypes was small. We found an inverse association
between IGF-I and “other subtypes of BCL”, although this
category includes those cases for which the BCL subtype is
Table 2. Odds ratios (95% confidence intervals) for all lymphoma and for lymphoma subclasses by third of IGF-I concentration
Third of IGF-I
1 (Reference) 2 3 p for trend1
All lymphoma
Cases/controls, n 397/358 339/357 336/357
OR (95% CI)2 1.00 (ref) 0.85 (0.69–1.05) 0.83 (0.67–1.04) 0.05
Multivariable-adjusted OR (95% CI)3 1.00 (ref) 0.85 (0.69–1.05) 0.82 (0.65–1.02) 0.06
BCL subtypes4
DLBCL
Cases/controls (n) 33/40 50/46 41/38
OR (95% CI)2 1.00 1.31 (0.72–2.36) 1.34 (0.68–2.64) 0.6
FL
Cases/controls (n) 44/38 35/32 36/45
OR (95% CI)2 1.00 0.94 (0.50–1.77) 0.66 (0.34–1.27) 0.2
B-CLL
Cases/controls (n) 67/56 56/66 61/62
OR (95% CI)2 1.00 0.71 (0.42–1.17) 0.82 (0.48–1.39) 0.3
MM
Cases/controls (n) 99/92 68/80 70/65
OR (95% CI)2 1.00 0.81 (0.54–1.22) 1.00 (0.64–1.56) 0.6
Other subtypes of BCL5
Cases/controls (n) 97/75 72/63 68/99
OR (95% CI)2 1.00 0.90 (0.57–1.41) 0.46 (0.28–0.75) 0.004
T-NHL
Cases/controls (n) 11/12 12/13 11/9
OR (95% CI)2 1.00 1.08 (0.25–4.70) 1.40 (0.34–5.81) 0.6
HL
Cases/controls (n 13/15 18/20 20/16
OR (95% CI)2 1.00 1.15 (0.41–3.18) 1.85 (0.52–6.60) 0.5
Other subtypes of lymphoma
Cases/controls (n) 33/30 28/37 29/23
OR (95% CI)2 1.00 0.68 (0.30–1.52) 1.11 (0.45–2.75) 0.5
Case patients and control participants were matched on recruitment centre, age at enrolment (66 months), time of day of blood collection (61 hr),
follow-up time (as close as possible), time between blood draw and last consumption of food or drinks (<3, 3–6, >6 hr).
1p Value from test of trend on 1 df based on continuous log concentration.
2ORs (95% CIs) are from conditional logistic regression models conditioned on the matching variables (above) but without additional adjustments
due to the small number of cases for these lymphoma subtypes.
3ORs (95% CIs) are from conditional logistic regression models conditioned on the matching variables (above) and additionally adjusted for smoking
(never, past, present), physical activity (inactive, moderately inactive, moderately active and active), alcohol intake (<8 g/day, 8–15 g/d, 16–39 g/
d, 40 g/d), marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary, degree level) and BMI (sex-
specific quartiles).
4BCL includes DLBCL, FL, B-CLL, MM and other subtypes of BCL.
5Those cases for which the BCL subtype is unknown or does not fall within the more common BCL subtypes (i.e. DBCL, FL, B-CLL or MM).
Abbreviations: N, number; BCL, B-cell lymphoma; B-CLL, B-cell chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular
lymphoma; HL, Hodgkin lymphoma; IGF-I, insulin-like growth factor I; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.
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Table 3. Odds ratios (95% confidence intervals) for all lymphoma by third of IGF-I concentration, subdivided by selected factors
Third of IGF-I
1 (ref.) 2 3 p for trend1 p for het. of trends
Overall 0.06
Cases/controls (n) 397/358 339/357 336/357
OR (95% CI)2 1.00 0.85 (0.69–1.05) 0.82 (0.65–1.03) 0.06
Sex 0.08
Men
Cases/controls (n) 187/187 182/186 190/186
OR (95% CI)2 1.00 0.98 (0.73–1.32) 1.02 (0.74–1.40) 0.8
Women
Cases/controls (n) 210/171 157/171 146/171
OR (95% CI)2 1.00 0.73 (0.53–1.01) 0.65 (0.46–0.90) 0.003
Age at blood collection 0.3
<60 yr
Cases/controls (n) 198/165 194/207 231/251
OR (95% CI)2 1.00 0.76 (0.57–1.01) 0.73 (0.54–1.01) 0.02
60 yr
Cases/controls (n) 192/183 139/145 99/102
OR (95% CI)2 1.00 0.91 (0.66–1.25) 0.89 (0.60–1.31) 0.6
Time between blood
collection and diagnosis
0.9
<48 mo
Cases/controls (n) 151/157 147/130 135/146
OR (95% CI)2 1.00 1.20 (0.84–1.70) 0.96 (0.66–1.41) 0.3
48 mo
Cases/controls (n) 246/201 192/227 201/211
OR (95% CI)2 1.00 0.71 (0.54–0.93) 0.74 (0.55–0.99) 0.1
Age at diagnosis3 0.2
<60 yr
Cases/controls (n) 92/90 118/133 175/162
OR (95% CI)2 1.00 0.84 (0.56–1.25) 1.02 (0.68–1.53) 0.9
60 yr
Cases/controls (n) 305/268 221/224 161/195
OR (95% CI)2 1.00 0.88 (0.68–1.14) 0.68 (0.51–0.91) 0.03
Body mass index 0.09
<25 kg/m2
Cases/controls (n) 72/53 61/73 61/68
OR (95% CI)2 1.00 0.64 (0.38–1.08) 0.59 (0.33–1.06) 0.01
25 kg/m2
Cases/controls (n) 166/142 119/141 128/126
OR (95% CI)2 1.00 0.70 (0.50–1.00) 0.76 (0.52–1.12) 0.3
Case patients and control participants were matched on recruitment centre, age at enrolment (66 months), time of day of blood collection (61 hr),
follow-up time (a0073 close as possible), time between blood draw and last consumption of food or drinks (<3, 3–6, >6 hr).
1p Value from test of trend on 1 df based on continuous log concentration.
2ORs (95% CIs) are from conditional logistic regression models conditioned on the matching variables (above) and additionally adjusted for smoking (nev-
er, past, present), physical activity (inactive, moderately inactive, moderately active and active), alcohol intake (<8 g/d, 8–15 g/d, 16–39 g/d, 40 g/d),
marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary, degree level) and BMI (sex-specific quartiles).
3Age at diagnosis for cases, and for each control their corresponding age at the date of diagnosis of the matched case.
Abbreviations: N, number; IGF-I, insulin-like growth factor I.
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unknown or does not fall within the more common BCL
subtypes (i.e. DBCL, FL, B-CLL or MM), and therefore con-
clusions on risk cannot be drawn.
While there was no signiﬁcant heterogeneity by time
between blood collection and diagnosis, there was a suggestion
of association only in those diagnosed 2 or more years after
recruitment and not in those diagnosed in the ﬁrst 2 years of
follow-up. Further prospective data are needed, but these
results suggest that reverse causality is unlikely to account for
our ﬁndings. Also, we found no evidence of signiﬁcant hetero-
geneity by sex, age at blood collection, age at diagnosis, or
body mass index. However, signiﬁcant trends in women, in
person 60 years and older, and in normal weight participants
were found. It is possible that we did not observe heterogenei-
ty by sex, age and BMI because of the limited sample size in
subgroups and, therefore, further prospective data are needed
to explore possible potential differences by sex, age and BMI.
Strengths of the current analysis include the sample size, the
length of follow-up and the information available on lymphoma
subtypes. The distribution of IGF-I values among controls in
this study is similar to that observed in previous studies.21
This study also has some limitations. IGF-I concentrations
were measured only once; however, previous studies reported
moderately to high within-individual reproducibility for IGF-
I measured in repeated blood samples collected up to 5 years
apart (intraclass or Spearman rank correlations ranging
between 0.4 and 0.9).22–25 There was also a small number of
participants’ in some of the lymphomas subclasses and sub-
groups deﬁned by participants characteristics, and also a rela-
tively high proportion of BCL not assigned to a speciﬁc BCL-
subtype, limiting the statistical power to detect an association
with speciﬁc lymphoma subtypes and subgroups. We were
not able to investigate the role of early life factors, such as
prenatal growth. It remains possible that under- and overnu-
trition in utero may lead to an elevated risk of developing
lymphoma in later life and to reprogramming of the IGF-I
axis. Previous studies have found heterogeneity by sample
media (e.g. serum or plasma) or type of assay,2 and this
should be taken into consideration in future studies. It is also
not possible to rule out residual confounding; in particular
we were unable to investigate potential confounding factors
related to non-steroidal anti-inﬂammatory drugs, infections
or birthweight. Finally, data on other IGFs and IGF-binding
proteins were not available in the current study.
In conclusion, these results suggest no association between
IGF-I and overall lymphoma risk. Further prospective data
are required to investigate the relationship of IGF-I with lym-
phoma subtypes.
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